09/06/21 -"With COVID-19 vaccine programmes fast gaining pace, a gradual recovery is expected in the Anti-Histamine markets heading into H2 21, indicating increasing demand for the high-margin drug, Bilastine. ..."
Pages
46
Language
English
Published on
09/06/21
You may also be interested by these reports :
12/12/25
Eli Lilly’s Retatrutide grabbed headlines with c.29% weight-loss efficacy in late-stage trials for obese patients who also had knee osteoarthritis. ...
08/12/25
Despite US tariff threats, drug pricing pressures and the persistent insistence from the US government to reshore manufacturing, the AV Big Pharmas ...
05/12/25
Against the backdrop of strong execution, with two outlook upgrades in 2025, backed by vigorous growth across all its focus areas (oncology, ...
28/11/25
Novo’s investors losing more weight than its patients